Tag «SELETALISIB»

SELETALISIB, селеталисиб , سيلستاليسيب , 司来利塞 ,

It’s only fair to share… SELETALISIB CAS 1362850-20-1 UCB-5857 , Plaque psoriasis,Sjoegren’s syndrome,Immunodeficiency disorders PHASE 3 UCB 23H14ClF3N6O , 482.85 Phosphatidylinositol 3 kinase delta (PI3Kδ) inhibitors 10023 1362850-20-1 [RN] N-{(1R)-1-[8-Chlor-2-(1-oxido-3-pyridinyl)-3-chinolinyl]-2,2,2-trifluorethyl}pyrido[3,2-d]pyrimidin-4-amine N—{(R)-1-[8-Chloro-2-(pyridin-3-yl)quinolin-3-yl]-2,2,2-trifluoroethyl}N-(1-oxypyrido-[3,2-d]pyrimidin-4-yl)amine Pyrido[3,2-d]pyrimidin-4-amine, N-[(1R)-1-[8-chloro-2-(1-oxido-3-pyridinyl)-3-quinolinyl]-2,2,2-trifluoroethyl]- 3-{8-chloro-3-[(1R)-2,2,2-trifluoro-1-({pyrido[3,2-d]pyrimidin-4-yl}amino)ethyl]quinolin-2-yl}pyridin-1-ium-1-olate селеталисиб [Russian] [INN] سيلستاليسيب [Arabic] [INN] 司来利塞 [Chinese] [INN] N-[(1R)-1-[8-chloro-2-(1-oxidopyridin-1-ium-3-yl)quinolin-3-yl]-2,2,2-trifluoroethyl]pyrido[3,2-d]pyrimidin-4-amine Seletalisib has been used in trials studying the treatment and basic science of Primary Sjogren’s Syndrome. Originator UCB Class Anti-inflammatories; Small molecules Mechanism …